<DOC>
	<DOCNO>NCT00809133</DOCNO>
	<brief_summary>The main purpose study assess optimum dose follow medication give together : - BIBW 2992 paclitaxel ( Taxol ) - BIBW 2992 paclitaxel bevacizumab ( Avastin ) - BIBW 2992 carboplatin - BIBW 2992 paclitaxel carboplatin The effect different drug combination also assess .</brief_summary>
	<brief_title>Trial Exploring Afatinib ( BIBW 2992 ) + Paclitaxel ( Part A ) , Afatinib + Paclitaxel + Bevacizumab ( Part B ) , Afatinib + Carboplatin ( Part C ) Afatinib+ Paclitaxel +Carboplatin ( Part D ) Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient ( patient ) histologically confirm diagnosis malignancy advance , nonresectable / metastatic . 2 . Age 18 year old old . 3 . Life expectancy least 3 month . 4 . Written inform consent consistent ICHGCP guideline . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 6 . Patients must recover previous surgery . 7 . Adequate organ function include follow : 8 . Cardiac leave ventricular function rest ejection fraction great equal 50 % 9 . Absolute neutrophil count great equal 1,500/microlitres ; great 2000/microlitres carboplatin 10 . Platelets great equal 100,000/microlitres 11 . Total bilirubin less equal 1.5 mg/dl ( &lt; 26 micromol /L , SI unit equivalent ) . 12 . AST ( SGOT ) /ALT ( SGPT ) less equal 2.5 X institutional upper limit normal . 13 . Creatinine le equal 1.5 mg/dl ( less equal 132 micromol per liter , SI unit equivalent ) . 14 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) duration trial participation . Female patient reproductive potential must negative serum pregnancy test within 7 day trial enrolment . Breast feed mother exclude since agent may toxic infant . Exclusion criterion : 1 . Active infectious disease 2 . Serious illness concomitant nononcological disease consider investigator incompatible protocol 3 . GI tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . 4 . Significant cardiovascular disease ( history congestive heart failure require therapy , need antiarrhythmic therapy ventricular arrhythmia , unstable angina pectoris myocardial infarction within 6 month prior trial entry ) . 5 . Patients require fulldose anticoagulation . 6 . Patients completely recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapies CTC less equal Grade 1 . Prior chemotherapy allow complete least 4 week prior 1st trial treatment ( 6 week mitomycin C nitrosoureas ) patient recover acute toxicity therapy . 7 . Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least 8 week , history cerebral oedema bleed past 8 week requirement steroid antiepileptic therapy 8 . Persistent Grade 2 great neurotoxicity / neuropathy cause . 9 . Patients immunosuppressant therapy know HIV infection . 10 . Treatment follow within 4 week start trial medication , trial , permit : chemo , immuno , radio ( small field palliative radiotherapy allow provided represent clear disease progression ) , biological therapy ( include trastuzumab ) , hormone therapy ( exclude LHRH agonist prostate cancer , bisphosphonates ) , treatment investigational drug . 11 . Participation another clinical trial within past 4 week start therapy concomitantly trial . 12 . Prior treatment EGFR target therapy treatment EGFR HER2 inhibit drug within past 4 week start therapy concomitantly trial . 13 . Patients know suspected hypersensitivity trial drug , excipients similar compound . 14 . Patients unable comply protocol . 15 . Active alcohol drug abuse . 16 . Patients know preexist interstitial lung disease Additional exclusion criterion patient recruit cohort B : 17 . Patients know suspected hypersensitivity bevacizumab , excipients Chinese hamster ovary cell product recombinant human humanise antibody . 18 . Patients brain metastasis ( brain scan require unless patient show sign symptom brain metastasis brain scan perform rule presence brain metastasis ) . 19 . Patients intraabdominal inflammation . 20 . Major surgery within 4 week start treatment wound ( ) deem investigator pose significant risk patient event delay healing . 21 . Prior treatment anthracycline and/or prior radiation chest wall ( patient category enter study investigator deem benefit patient outweigh risk ) . 22 . Patients follow condition : significant hypertension , significant haemoptysis , know brian metastasis , thrombotic haemorrhagic disorder , INR great equal 1.5 abnormal PTT , therapeutic anticoagulation , squamous non small cell lung cancer Additional exclusion criterion patient recruit cohort C D Patients severe myelosuppression ; i.e . absolute neutrophil count le 2000/microlitres Patients renal impairment ( creatinine clearance less 60ml per minute CockcroftGault equation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>